$CELG News The market puts a few feathers in its cap 1:58

New Post Public Reply Private Reply Replies (0) Message Board

Feb 26, 2014 at 12:28 PM

$CELG News

The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck

Putting the biotech boom in perspective 12:54 p.m. Feb. 24, 2014 - Seeking Alpha
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Feb. 24, 2014 - TheStreet.com
Catalysts Drive These Stocks: Mara Goldstein 9:20 a.m. Feb. 21, 2014 - Seeking Alpha
Can CELG Clear Key Resistance? 9:00 a.m. Feb. 21, 2014 - RealMoney.com
Placenta Based Treatments Crowding Out Legacy Products In Wound Care 8:34 a.m. Feb. 21, 2014 - Seeking Alpha
Who Is Responsible For Biotech's Torrid Start to 2014? 4:03 p.m. Feb. 20, 2014 - TheStreet.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Celgene Corporation (CELG): Today's Featured Health Care Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Celgene Plans Stock Split - Analyst Blog 5:34 p.m. Feb. 14, 2014 - Zacks.com
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
10-K: CELGENE CORP /DE/ 4:04 p.m. Feb. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day Winning Streak 3:50 p.m. Feb. 13, 2014 - benzinga.com
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin 9:23 a.m. Feb. 13, 2014 - Seeking Alpha
IPO Preview: Concert Pharmaceuticals 1:00 a.m. Feb. 13, 2014 - Seeking Alpha
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 5:08 p.m. Feb. 12, 2014 - TheStreet.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Celgene Corporation Continues With Buy Recommendation 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma 6:30 a.m. Feb. 11, 2014 - CNW Group
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com

Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split 7:30 a.m. Feb. 13, 2014 - BusinessWire - BZX
Celgene Corporation to Present at Investor Conferences in February and March 8:30 a.m. Feb. 11, 2014 - BusinessWire - BZX
Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. of Off-Label Marketing of High-Risk Cancer Drugs Derived from Thalidomide 2:11 p.m. Feb. 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Endo Pharmaceuticals, Mattel, Celgene, and Tyson Foods Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results 7:32 a.m. Jan. 30, 2014 - BusinessWire - BZX
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 8:30 a.m. Jan. 22, 2014 - BusinessWire - BZX
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...